CAS · 73963-72-1
Product Overview
Cilostazol is a high-purity a-api supplied for industrial and specialty chemical applications. Contact our team for specifications, packaging options and lead times.
Product Specifications
| Grade | USP43 |
|---|---|
| Characters | White to light yellow crystalline powder |
| Assay by HPLC (on dried basis) | 98% to 102% |
| Identification A | The IR spectrum is consistent with that obtained with Cilostazol RS |
| Identification B | The retention time of the major peak in the chromatogram of the Assay preparation corresponds to that in the chromatogram of the Standard preparation |
| Loss on Drying | 0.3% max |
| Residue on Ignition | 0.1% max |
| Chloride | 0.018% max |
| Heavy Metals | 0.001% max |
| Particle size | 90% less than 10 μm; 10% less than 20 μm |
| Impurity A | 0.1% max |
| Impurity B | 0.1% max |
| Impurity C | 0.1% max |
| Any other individual impurity | 0.1% max |
| Total impurities | 0.4% max |
| Residual Solvents N, N-Dimethylacetamide | 1090 ppm max |
| Chloroform | 60 ppm max |
| Ethanol | 3000 ppm max |
| Methanol | 3000 ppm max |
| Microbial Limits Total aerobic microbial count | 2000 cfu/g max |
| Total combined molds & yeasts | 200 cfu/g max |
| Other specific microorganisms | Absent (E.Coli, Salmonella sp) |
Applications
Cilostazol is primarily used as a therapeutic agent for the management of peripheral arterial disease and intermittent claudication, improving blood flow and walking distance in affected patients. It functions as a phosphodiesterase III inhibitor, which leads to vasodilation and inhibition of platelet aggregation. Cilostazol is formulated in oral tablets for chronic therapy and is also investigated in combination with other cardiovascular drugs for the treatment of stroke, coronary artery disease, and other vascular disorders. Beyond clinical applications, it is utilized in pharmaceutical research for developing new derivatives targeting vascular health and antiplatelet therapy.
Benefits
The benefits of Cilostazol include its dual action of vasodilation and antiplatelet activity, which helps improve circulation and reduce the risk of thrombotic events. By inhibiting platelet aggregation without significant effects on coagulation factors, it lowers the risk of bleeding complications compared to some other antiplatelet agents. It enhances walking distance and overall exercise tolerance in patients with peripheral artery disease, improving quality of life. Cilostazol also exhibits a favorable safety profile and is well tolerated in long-term use, making it suitable for chronic cardiovascular management.
Conclusion
Cilostazol is a valuable cardiovascular drug that supports vascular health and improves mobility in patients with peripheral arterial disease. Its benefits, including vasodilation, antiplatelet activity, and safety in long-term use, make it an important option in cardiovascular therapy. By enhancing circulation and reducing thrombotic risks, Cilostazol continues to play a significant role in improving patient outcomes and managing vascular disorders.
Previous
Sevelamer Hydrochloride丨CAS 152751-57-0
Next